Qiagen.com

QIAGEN.COM NEWSROOM (34 press releases)

Advanced Filtering & Sorting Options:

France’s Ministry of Health and Social Affairs approves reimbursement for QIAGEN’s QuantiFERON-TB® Gold Plus latent tuberculosis test

PRESS RELEASE -- 23, June 2017

Gold-standard test for latent tuberculosis infection will be covered by national health insurance Hilden, Germany, and Paris, France, 23-Jun-2017 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France’s Ministry of Health and Social Affairs … Read the full press release

DiaSorin, QIAGEN to develop new tests for DiaSorin’s LIAISON family of analyzers

PRESS RELEASE -- 23, June 2017

Saluggia, Italy; Hilden, Germany, and Germantown, Maryland, USA, 23-Jun-2017 — /EuropaWire/ — DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) announced today a new collaboration to develop new tests for DiaSorin’s LIAISON family of … Read the full press release

U.S. FDA premarket approval for QIAGEN’s automated artus® CMV QS-RGQ MDx kit for use on its QIAsymphony platform

PRESS RELEASE -- 7, June 2017

High-throughput application of artus CMV QS-RGQ MDx Kit on QIAsymphony streamlines critical and frequently performed viral infection test for transplant patients Germantown, Maryland, and Hilden, Germany, 07-Jun-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has … Read the full press release

QIAGEN receives worldwide license from The Johns Hopkins University for biomarkers for immune-oncology therapies in cancer treatment

PRESS RELEASE -- 7, June 2017

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland, 07-Jun-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide … Read the full press release

Bristol-Myers Squibb and QIAGEN to explore NGS technology to develop GEPs for I-O therapies in cancer treatment

PRESS RELEASE -- 6, June 2017

NEW YORK and HILDEN, Germany, 06-Jun-2017 — /EuropaWire/ — Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  … Read the full press release

QIAGEN N.V. forms joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China

PRESS RELEASE -- 8, May 2017

Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world’s first complete Sample to Insight NGS solution in rapidly growing Chinese market Hilden, Germany, and Chengdu, China, 08-May-2017 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt … Read the full press release

QIAGEN N.V. and Hamilton Robotics to serve the growing need for DNA fingerprinting of samples for human identity databases

PRESS RELEASE -- 13, October 2016

Partnering with Hamilton Robotics to deliver automated workflows for DNA fingerprinting  Hilden, Germany, and Germantown, Maryland, 13-Oct-2016 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of automated high-throughput solutions, developed in partnership with Hamilton … Read the full press release

QIAGEN N.V. to submit conditional voluntary takeover offer to purchase all shares in Exiqon

PRESS RELEASE -- 1, April 2016

Transaction will expand leadership position in RNA technologies Venlo, The Netherlands, 01-Apr-2016 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of … Read the full press release

Evaluation affirms the performance of the QIAGEN’s GeneReader NGS System in detecting gene variants known to be clinically relevant in colorectal cancer

PRESS RELEASE -- 6, November 2015

World’s first complete Sample to Insight NGS solution proves equal or better compared with other sequencing workflows and alternative technologies Austin, Texas, and Hilden, Germany, 6-11-2015 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an … Read the full press release

QIAGEN N.V. starts commercialization activities for its GeneReader NGS System

PRESS RELEASE -- 6, November 2015

First truly end-to-end solution brings next-generation sequencing within reach for any lab Austin, Texas, and Hilden, Germany, 6-11-2015 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the start of commercialization activities for its GeneReader NGS System, … Read the full press release

QIAGEN N.V. to increase global access to advanced cervical cancer screening technologies for women most in need

PRESS RELEASE -- 17, September 2015

Global launch of CE marked careHPV and new CE marked self-collection claim for HPV sampling device help to provide HPV screening for women most in need HILDEN, Germany, 17-9-2015 — /EuropaWire/ — QIAGEN N.V. today announced its latest initiative to increase … Read the full press release

QIAGEN N.V. announces new capabilities for its Ingenuity® Variant Analysis™ and CLC Cancer Research Workbench solution

PRESS RELEASE -- 21, October 2014

Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human Genetics annual meeting Volume of 250,000-plus DNA samples linked to Ingenuity® Knowledge Base greatly exceeds any comparable database – providing … Read the full press release

QIAGEN N.V. released Q2 and H1 2013 results and announced new share repurchase program

PRESS RELEASE -- 9, August 2013

Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $83.4 million; adjusted diluted EPS of $0.27 per shareNew program authorized to repurchase up to $100 million in QIAGEN shares … Read the full press release

QIAGEN gains SFDA approval to market careHPV Test in China – expanding access to HPV testing in low-resource countries

PRESS RELEASE -- 6, December 2012

Commercial launch of careHPV in China and other emerging markets will enable high-quality screening for prevention of cervical cancer “Country of Origin” approval key for dissemination, other countries are able to use this as a basis for registration care HPV is the first HPV test designed … Read the full press release